CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Elanco against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline AnimalsBOEHRINGER INGELHEIM VETMEDICAJul 24, 2024
Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing ThemBOEHRINGER INGELHEIM ANIMAL HEALTH USANov 22, 2021
Treatment Of Coccidiosis With Intramuscular Triazine CompositionsCEVA SANT ANIMALEMay 5, 2021
Salmonid Alphavirus VaccineINTERVETApr 29, 2021
Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In PigsBOEHRINGER INGELHEIM ANIMAL HEALTH USAApr 29, 2021
Multivalent Pcv2 Immunogenic Compositions And Methods Of Producing Such CompositionsBOEHRINGER INGELHEIM ANIMAL HEALTH USAFeb 25, 2021
New Treatments With TriazinesCEVA SANT ANIMALEDec 18, 2020
Vaccine Against Porcine Circo Virus Type 2INTERVETOct 14, 2020
Treatment Of Coccidiosis With Intramuscular Triazine CompositionsCEVA SANT ANIMALEJun 1, 2020
Pcv2 Immunogenic Compositions And Methods Of Producing Such CompositionsBOEHRINGER INGELHEIM ANIMAL HEALTH USAJan 10, 2020

Explore Elanco's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Oct 16, 2024Controlled Release Compositions And Their Methods Of Use1
Jan 26, 2022Compositions Of Grapiprant And Methods For Using The Same2
Oct 2, 2019Injectable Antibiotic Formulations And Their Methods Of Use2
Dec 6, 2017New Combination1

Top competitors of Elanco

List of top competitors of Elanco based on patent oppositions.